Meningococcal Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Meningococcal Vaccines Market By Type (Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine), By End user (Hospitals, Clinic, Others )and By Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global meningococcal vaccine market size valued at $ 2.77 billion in 2020 and expected to reach $ 5.92 billion in 2027, growing at a CAGR of 9.14% from 2021 to 2027. Meningococcal disease is a fatal disease caused by a bacteria called as Neisseria Meningitides which cause potential infection in the meninges, the thin layers of connective tissues which surrounds spinal cord and brain. Common symptoms are bacteraemia, pneumonia and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes and lethargy. Surge in incidence of meningococcal disease is expected to play vital role in growth of the global meningococcal vaccines market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions. According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has had such a negative impact on humanity that various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of disease, government initiatives, increase R&D investments by various players, introduction of advanced vaccines are expected to boost growth of meningococcal vaccines market. However, lack of awareness, high cost of vaccines, unfavourable regulatory conditions are restrains of global meningococcal vaccines market.

Meningococcal Vaccines Market

MARKET SUMMARY
-
9.14% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 9.14%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Meningococcal Vaccines Market

  • The report on global meningococcal vaccines market gives historical, current and future market sizes (US$ Bn) on the basis of by type, by end-user and geography.
  • meningococcal vaccines market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • GlaxoSmithKline plc.
  • JN-International Medical Corporation
  • Novartis International AG
  • Sanofi
  • Pfizer
  • Baxter International, Inc.
Meningococcal Vaccines Market

Drivers And Restraints

Rise in incidence and mortality rate of meningococcal disease is expected to create lucrative growth opportunities for the global market. Favourable government initiatives are expected create awareness among people. For example, by 2018 MenA conjugate vaccines programmes in Africa is anticipated to prevent around 1, 23, 000 deaths. Meningococcal vaccine market is high consolidated market with very few market players. It is experiencing at rapid growth due to new products and it is expected to experience tremendous growth due to new entrants into the market during the forecast period.


North-America got significant share

Meningococcal Vaccines Market

Global Market is segmented as Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America Market is expected to dominate revenue share followed by Europe, owing to increase in population and rise in prevalence of meningococcal diseases among population. U.S. meningococcal vaccines market is accounted for major regional revenue share. In Europe, Germany, UK and France hold the largest share owing to rise in several initiatives taken by the government, well established healthcare infrastructure. Asia Pacific is expected to show a significant growth owing to growing awareness among consumers, rise in disposable income and various government immunization initiatives to eradicate meningococcal disease in Asia Pacific.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

In October 2014, Pfizer received U.S. FDA approval for its TRUMENBA (meningococcal group B vaccine) to prevent meningococcal disease.


Key

Key Features of the Report

Meningococcal Vaccines Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • GlaxoSmithKline plc. (UK)
  • JN-International Medical Corporation (U.S.)
  • Novartis International AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc. (U.S.)
  • Baxter International, Inc. (U.S.)

Description

The global meningococcal vaccine market size valued at $ 2.77 billion in 2020 and expected to reach $ 5.92 billion in 2027, growing at a CAGR of 9.14% from 2021 to 2027. Meningococcal disease is a fatal disease caused by a bacteria called as Neisseria Meningitides which cause potential infection in the meninges, the thin layers of connective tissues which surrounds spinal cord and brain. Common symptoms are bacteraemia, pneumonia and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes and lethargy. Surge in incidence of meningococcal disease is expected to play vital role in growth of the global meningococcal vaccines market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions. According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has had such a negative impact on humanity that various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of disease, government initiatives, increase R&D investments by various players, introduction of advanced vaccines are expected to boost growth of meningococcal vaccines market. However, lack of awareness, high cost of vaccines, unfavourable regulatory conditions are restrains of global meningococcal vaccines market.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX